Clinical Trials Browser

Pathologic Complete Response, Neoplasms, Sarcoma

NCT04126590 2023-09-01

Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors

Phase 1 Unknown

39 enrolled

Pathologic Complete Response

NCT05750693 2023-03-02

PIK3CA in HER2+ BC and pCR Trial

Phase NA Unknown

58 enrolled

Pathologic Complete Response, Hereditary Sensory and Autonomic Neuropathies

NCT04781725 2021-11-17

INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

Phase 2 Unknown

90 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT02907827 2020-12-17

DW-MRi

Phase NA Unknown

100 enrolled

Dermatologic

Pathologic Complete Response, Melanoma

NCT03417427 2020-04-27

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

Phase 2 Unknown

100 enrolled

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT04006041 2019-12-26

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Phase 2 Unknown

44 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response

NCT01863862 2019-03-29

Organ Preservation in Elderly Patients With Rectal Cancer

Phase NA Unknown

90 enrolled

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT01830244 2017-07-02

Neonab

Phase 2 Unknown

60 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT01520558 2017-06-29

CNDO-109-AANK for AML in First Complete Remission (CR1)

Phase 1/2 Unknown

12 enrolled 11 charts

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT02511847 2016-04-15

Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib

Phase 2 Unknown

40 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02059876 2014-02-12

Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer

Phase 2 Unknown

60 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT01134484 2012-07-20

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

Phase 3 Unknown

480 enrolled

Plasma cell

Pathologic Complete Response, Multiple Myeloma

NCT01566799 2012-03-30

Metformin Plus Neoadjuvant Chemotherapy in Breast Cancer

Phase 2 Unknown

60 enrolled

Pathologic Complete Response

Clinical Trials

SarQuantIRM

Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors

PIK3CA in HER2+ BC and pCR Trial

INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

DW-MRi

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Organ Preservation in Elderly Patients With Rectal Cancer

Neonab

CNDO-109-AANK for AML in First Complete Remission (CR1)

Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib

Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

Metformin Plus Neoadjuvant Chemotherapy in Breast Cancer